Home » Stocks » CORT

Corcept Therapeutics Incorporated (CORT)

Stock Price: $22.79 USD 0.03 (0.11%)
Updated Apr 19, 2021 2:03 PM EDT - Market open
Market Cap 2.67B
Revenue (ttm) 353.87M
Net Income (ttm) 106.01M
Shares Out 115.41M
EPS (ttm) 0.85
PE Ratio 26.81
Forward PE 22.78
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $22.79
Previous Close $22.77
Change ($) 0.03
Change (%) 0.11%
Day's Open 22.68
Day's Range 22.30 - 22.83
Day's Volume 259,437
52-Week Range 11.91 - 31.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

With solid revenue growth, these stocks have the potential to more than triple over the next few years.

Other stocks mentioned: CPRX, SUPN
3 weeks ago - The Motley Fool

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

1 month ago - Zacks Investment Research

MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...

1 month ago - GlobeNewsWire

Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.

1 month ago - Zacks Investment Research

MENLO PARK, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...

1 month ago - GlobeNewsWire

AMRX vs. CORT: Which Stock Is the Better Value Option?

Other stocks mentioned: AMRX
2 months ago - Zacks Investment Research

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...

Other stocks mentioned: ACST
2 months ago - Benzinga

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021.

2 months ago - Zacks Investment Research

Financial Highlights, 2021 Revenue Guidance and Legal Update

2 months ago - GlobeNewsWire

Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results ...

2 months ago - GlobeNewsWire

Time will always be on the investor's side.

Other stocks mentioned: CRSP, FATE, JNCE, LXRX
2 months ago - The Motley Fool

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

3 months ago - Zacks Investment Research

On Friday, Corcept Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Corcept Therapeutics Sees Its Composite Rating Rise To 96 appeared first on Investor's Bus...

4 months ago - Investors Business Daily

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...

4 months ago - GlobeNewsWire

Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB. The post Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24...

5 months ago - InvestorPlace

MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...

5 months ago - GlobeNewsWire

Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year.

5 months ago - Zacks Investment Research

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript

5 months ago - Seeking Alpha

Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 22.58% over the past year to $0.24, which...

5 months ago - Benzinga

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on No...

5 months ago - GlobeNewsWire

A patent decision on its cortisol therapy Korlym is expected to be rendered next month.

6 months ago - The Motley Fool

Growth-focused investors may be interested in the following stocks since their price-earnings ratios still trade below 20 and their trailing 12-month earnings per share have grown significantly over the...

Other stocks mentioned: LL, PDEX
7 months ago - GuruFocus

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well.

7 months ago - Zacks Investment Research

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe me...

7 months ago - GlobeNewsWire

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.

Other stocks mentioned: ATNX, CAL, DXC, TWTR
7 months ago - GuruFocus

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.

8 months ago - Business Wire

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

8 months ago - Zacks Investment Research

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...

8 months ago - GlobeNewsWire

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on...

8 months ago - GlobeNewsWire

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...

8 months ago - GlobeNewsWire

MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...

8 months ago - GlobeNewsWire

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Other stocks mentioned: QDEL, VEEV, VRTX
9 months ago - Investors Business Daily

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared first on Inve...

Other stocks mentioned: ALXN, VRTX
9 months ago - Investors Business Daily

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

9 months ago - Zacks Investment Research

MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...

10 months ago - GlobeNewsWire

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: DVAX, GTHX, IMGN, KDMN, SUPN, VRTX
10 months ago - InvestorPlace

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

Is (CORT) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

MENLO PARK, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...

11 months ago - GlobeNewsWire

This biotech company has seen huge growth over the past five years.

11 months ago - The Motley Fool

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cu... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Joseph Belanoff
Employees
236
Stock Exchange
NASDAQ
Ticker Symbol
CORT
Full Company Profile

Financial Performance

In 2020, CORT's revenue was $353.87 million, an increase of 15.46% compared to the previous year's $306.49 million. Earnings were $106.01 million, an increase of 12.56%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 27.00, which is an increase of 18.47% from the latest price.

Price Target
$27.00
(18.47% upside)
Analyst Consensus: Buy